The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Open accessAbstract
Trying to kill cancer cells by generating DNA damage is by no means a new idea. Radiotherapy and genotoxic drugs are routinely used in cancer therapy. More recent developments also explored the potential of targeting the DNA damage response (DDR) in order to increase the toxicity of radio‐ and chemo‐ therapy. Chk1 inhibitors have pioneered studies in this regard. Interestingly, early studies noted that Chk1 inhibitors were particularly toxic for p53‐deficient cells. The model proposed for this observation was that this effect was due to the simultaneous abrogation of the G2 (Chk1) and G1 (p53) checkpoints. We here challenge this view, and propose a model where the toxicity of Chk1 inhibitors is rather due to the fact that these compounds generate high loads of replicative stress (RS) during S‐phase, which are further boosted by the less restrictive S‐phase entry found in p53‐deficient cells. This new model implies that the particular toxicity of Chk1 inhibitors might not be restricted to p53‐deficient cells, but could be extended to other mutations that promote a promiscuous S‐phase entry. In addition, this rationale also implies that the same effect should also be observed for other molecules that target the RS‐response (RSR), such as inhibitors of the Chk1‐activating kinase ATR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“Previous work had shown that AT patients had a deficient upregulation of p53 levels in response to DNA damage, which was associated with a weaker G1/S checkpoint (Kastan et al., 1992).”
BackgroundA Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) · Science · doi:10.1126/science.7792600 · Cited by 2,785 · cited 1×
“…of Chk1 and a full activation of the RSR. Pioneering work from Yossi Shiloh and colleagues led to the identification of a kinase that was responsible for the radiosensitivity observed in patients of a rare hereditary disease known as Ataxia Telangiectasia (AT) (Savitsky et al., 1995).”
BackgroundSensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · cited 1×
“Soon after the link of ATM with radiation responses was established, Karlene Cimprich cloned an ATM and Rad-3 related kinase known as ATR (Cimprich et al., 1996).”
BackgroundThe DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · cited 14×
“The RSR: time to fly solo from the DDR repair of these genomic lesions, while at the same time limits DNA double-strand breaks (DSB) are amongst the most deleterious lesions that cells can suffer.”
BackgroundInfluential
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
ATR phosphorylates SMARCAL1 to prevent replication fork collapse
Couch, F. B., Bansbach, C. E., Driscoll, R., Luzwick, J. W., Glick, G. G., Bétous, R., Carroll, C. M., Jung, S. Y., Qin, J., Cimprich, K. A., et al. (2013) · Genes & Development · doi:10.1101/gad.214080.113 · Cited by 406
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Self-citationKolinjivadi, A. M., Sannino, V., De Antoni, A., Zadorozhny, K., Kilkenny, M., Técher, H., Baldi, G., Shen, R., Ciccia, A., Pellegrini, L., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.001 · Cited by 372
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 265
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
Celebi, R., Bear Don’t Walk, O., Movva, R., Alpsoy, S., & Dumontier, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45236-6 · Cited by 120
Beier, F., Foronda, M., Martinez, P., & Blasco, M. A. (2012) · Blood · doi:10.1182/blood-2012-03-418038 · Cited by 79
Flis, S., Gnyszka, A., & Flis, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092305 · Cited by 53
Menendez, D., Anand, J. R., Murphy, C. C., Bell, W. J., Fu, J., Slepushkina, N., Buehler, E., Martin, S. E., Lal-Nag, M., Nitiss, J. L., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28195 · Cited by 22
Importin β-dependent nuclear import of TopBP1 in ATR–Chk1 checkpoint in Xenopus egg extracts
Bai, L., Michael, W. M., & Yan, S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.006 · Cited by 19
DDRprot: a database of DNA damage response-related proteins
Andrés-León, E., Cases, I., Arcas, A., & Rojas, A. M. (2016) · Database · doi:10.1093/database/baw123 · Cited by 12
Metadata
- Authors
- Toledo, L. I., Murga, M., & Fernandez‐Capetillo, O.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2011-07-28
- Volume
- 5
- Issue
- 4
- Pages
- 368-373
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2024231564
- Cited by
- 175
- References
- 25
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.